AFT Pharmaceuticals (NZSE:AFT) Debt-to-Equity : 0.50 (As of Sep. 2023)

View and export this data going back to 2015. Start your Free Trial

What is AFT Pharmaceuticals Debt-to-Equity?

AFT Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was NZ$0.0 Mil. AFT Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was NZ$36.6 Mil. AFT Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Sep. 2023 was NZ$73.9 Mil. AFT Pharmaceuticals's debt to equity for the quarter that ended in Sep. 2023 was 0.50.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for AFT Pharmaceuticals's Debt-to-Equity or its related term are showing as below:

NZSE:AFT' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.5 Med: 1.22 Max: 14.17
Current: 0.5

During the past 8 years, the highest Debt-to-Equity Ratio of AFT Pharmaceuticals was 14.17. The lowest was 0.50. And the median was 1.22.

NZSE:AFT's Debt-to-Equity is ranked worse than
65.89% of 856 companies
in the Drug Manufacturers industry
Industry Median: 0.29 vs NZSE:AFT: 0.50

AFT Pharmaceuticals Debt-to-Equity Historical Data

The historical data trend for AFT Pharmaceuticals's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AFT Pharmaceuticals Debt-to-Equity Chart

AFT Pharmaceuticals Annual Data

Trend

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Debt-to-Equity

Get a 7-Day Free Trial

8.20

2.74

1.15

0.71

0.52

AFT Pharmaceuticals Semi-Annual Data
	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Debt-to-Equity	Get a 7-Day Free Trial											1.02	0.71	-	0.52	0.50

Competitive Comparison of AFT Pharmaceuticals's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, AFT Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AFT Pharmaceuticals's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AFT Pharmaceuticals's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where AFT Pharmaceuticals's Debt-to-Equity falls into.

AFT Pharmaceuticals Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

AFT Pharmaceuticals's Debt to Equity Ratio for the fiscal year that ended in Mar. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(3.029	+	35.02)	/	73.268
	=	0.52

AFT Pharmaceuticals's Debt to Equity Ratio for the quarter that ended in Sep. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	36.621)	/	73.906
	=	0.50

AFT Pharmaceuticals (NZSE:AFT) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

AFT Pharmaceuticals Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of AFT Pharmaceuticals's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

AFT Pharmaceuticals (NZSE:AFT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AFT Pharmaceuticals Ltd (NZSE:AFT) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

AFP:Australia

Address

129 Hurstmere Road, Level 1, Takapuna, Auckland, NTL, NZL, 0622

Website

https://www.aftpharm.com

AFT Pharmaceuticals Ltd is a pharmaceutical distributor and developer of pharmaceutical intellectual property. Some of the products of the organization are Aqueous cream, Calci-tab, Maxigesic, Cromo-fresh, Crystaderm, Crytawash, Ellgy plus, Emulsifying ointment, and others. The group has four operating segments based on geographical location being, Australia, New Zealand, Asia, and the Rest of the world. It generates the majority of the revenue from Australia which includes the sales and distribution activity relating to the Australian market.